Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Cempra's Solithera Draws FDA Complete Response Letter On Liver Risks

29 Dec 2016

• By Michael Cipriano

Bacterias 3D rendering

Related Content

Rx For Industry: Key Provisions Of The 21<sup>st</sup> Century Cures Act

09 Dec 2016

The Evolution Of 21<sup>st</sup> Century Cures Legislation

30 Nov 2016

Cempra’s Antibiotic Likely Needs Bigger Trial – But Might Be Able To Do It In Phase IV

05 Nov 2016

Cempra To Defend CABP Antibiotic's Safety At US FDA Advisory Panel

03 Nov 2016

FDA Worries About Off-Label Use, Stewardship With Limited-Population Approval Pathway

11 Feb 2013

Related Companies

Melinta Therapeutics, Inc.

Allergan plc

Hospira, Inc.

Pfizer Inc.

Wockhardt Limited

Additional Topics

United States Regulation Complete Response Letters Drug Review BioPharmaceutical Infectious Diseases

More from Complete Response Letters

More from Product Reviews

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.